Getein Biotech, Inc (SHA:603387)

China flag China · Delayed Price · Currency is CNY
8.45
+0.05 (0.60%)
Mar 10, 2026, 2:04 PM CST
-2.20%
Market Cap 4.26B
Revenue (ttm) 1.04B
Net Income (ttm) 208.76M
Shares Out 507.15M
EPS (ttm) 0.41
PE Ratio 20.47
Forward PE n/a
Dividend 0.18 (2.15%)
Ex-Dividend Date Sep 15, 2025
Volume 3,777,062
Average Volume 6,670,063
Open 8.44
Previous Close 8.40
Day's Range 8.38 - 8.48
52-Week Range 7.31 - 9.23
Beta 0.30
RSI 44.09
Earnings Date Apr 30, 2026

About Getein Biotech

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical immunity, and other fields, such as myocardium, inflammation, renal function, thyroid function, hormones, glucose metabolism, tumor, coagulation, blood... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2002
Employees 1,947
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603387
Full Company Profile

Financial Performance

In 2024, Getein Biotech's revenue was 1.16 billion, a decrease of -14.93% compared to the previous year's 1.37 billion. Earnings were 223.64 million, a decrease of -20.06%.

Financial Statements

News

There is no news available yet.